<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04634682</url>
  </required_header>
  <id_info>
    <org_study_id>RFT-MYO-2020-01</org_study_id>
    <nct_id>NCT04634682</nct_id>
  </id_info>
  <brief_title>Effect of MYODM on Quality of Life, Fatigue and Hypersomnia in Patients With Myotonic Dystrophy Type 1</brief_title>
  <official_title>Assessing the Effect of the MYODM Food Supplement on Quality of Life, Fatigue and Hypersomnia in Patients With Myotonic Dystrophy Type 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Myogem Health Company, S.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Myogem Health Company, S.L.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether MYODM (formulated composition containing&#xD;
      Theobroma cacao supplemented with caffeine (caffeine/theobromine ratio1/1.85, w/w) is&#xD;
      effective in the treatment of excessive daytime sleepiness due to myotonic dystrophy type 1&#xD;
      (DM1) and improves the quality of life of these patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detailed Description:&#xD;
&#xD;
      Myotonic Dystrophy type I (DM1) is the most common form of adult muscular dystrophy,&#xD;
      affecting 1 in 8000 individuals. It is an autosomal dominant disorder with multisystemic&#xD;
      involvement of multiple organs and tissues, mainly brain, heart, endocrine system, eyes and&#xD;
      both smooth and skeletal muscles.&#xD;
&#xD;
      Hypersomnolence is one of the most frequently reported symptoms in patients with DM1 and&#xD;
      often lead to handicap such as cessation of employment and withdrawal from social activities.&#xD;
      The present project is a 6 month randomized study to assess the effect of MYODM on fatigue,&#xD;
      hypersomnia and quality of life in DM1 patients.The patients will be randomized to one of the&#xD;
      two study arms. The active arm will receive the MYODM treatment and the control arm will not&#xD;
      but both will follow the same evaluation program.&#xD;
&#xD;
      Patients will come to the center every 3 months for evaluations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 9, 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Individualized Neuromuscular Quality of Life (INQoL) Mean Scores</measure>
    <time_frame>Screening, Month 3, Month 6</time_frame>
    <description>Scores from the self-administered INQoL questionnaire will be compared at the start of the study (Month 0) and at the end (Month 6) among the MYODM treated group and the control group. Scores range from 0-100, with 100 being a better outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Individualized Short Form-36 (SF-36) Mean Scores</measure>
    <time_frame>Screening, Month 3, Month 6</time_frame>
    <description>Scores from the self-administered SF-36 questionnaire will be measured at the start of the study (Month 0), and at the end (Month 6) among patients in the MYODM-treated group and control group. Mean scores range from 0 (minimum) - 100 (maximum) with higher mean scores reflecting better outcomes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Epworth Sleepiness Scale (ESS) Scores</measure>
    <time_frame>Screening, Month 3, Month 6</time_frame>
    <description>ESS score range is 0-24; lower ESS scores indicate less daytime sleepiness; higher ESS scores indicate more severe sleepiness</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Physical activity and daytime sleepiness measured with GeneActiv actometer</measure>
    <time_frame>Screening, Baseline, Month 6</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Myotonic Dystrophy 1</condition>
  <arm_group>
    <arm_group_label>MYODM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MYODM, three times a day, orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will follow the same evaluation schedule but will not receive MYODM</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>MYODM</intervention_name>
    <description>Formulated composition containing Theobroma cacao supplemented with caffeine</description>
    <arm_group_label>MYODM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
          -  Genetically proven DM1&#xD;
&#xD;
          -  Able to walk independently&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Regular intake of plant stanols or other nutritional supplement&#xD;
&#xD;
          -  Co-morbidity interfering with the interventions or possibly influencing outcomes.&#xD;
&#xD;
          -  Participation in another clinical trial at the same time&#xD;
&#xD;
          -  Unable to complete study questionnaires.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Universitario Donostia</name>
      <address>
        <city>San Sebasti√°n</city>
        <state>Guipuzkoa</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Fernandez Torron</last_name>
      <phone>943 00 70 27</phone>
      <email>roberto.fernandeztorron@osakidetza.eus</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 25, 2020</study_first_submitted>
  <study_first_submitted_qc>November 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2020</study_first_posted>
  <last_update_submitted>November 17, 2020</last_update_submitted>
  <last_update_submitted_qc>November 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myotonic Dystrophy</mesh_term>
    <mesh_term>Disorders of Excessive Somnolence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

